LENZ (LENZ Therapeutics) Change In Receivables: $-0.11 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $4.74
! 4 Warning Signs
View Full Analysis

What is LENZ Therapeutics Change In Receivables?

LENZ Therapeutics LENZ +2.83% 12 Change In Receivables is $-0.11 Mil as of Jun. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

LENZ Therapeutics's change in receivables for the quarter that ended in Jun. 2026 was $-0.10 Mil. It means LENZ Therapeutics's Accounts Receivable increased by $0.10 Mil from Mar. 2026 to Jun. 2026 .

LENZ Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was $-0.33 Mil. It means LENZ Therapeutics's Accounts Receivable increased by $0.33 Mil from Dec. 2024 to Dec. 2025 .

LENZ Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2026 was $0.44 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. LENZ Therapeutics's Days Sales Outstanding for the three months ended in Jun. 2026 was 7.35.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. LENZ Therapeutics's liquidation value for the three months ended in Jun. 2026 was $205.06 Mil.

LENZ Therapeutics  (NAS:LENZ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

LENZ Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.442/5.486*91
=7.35

2. In Ben Graham's calculation of liquidation value, LENZ Therapeutics's accounts receivable are only considered to be worth 75% of book value:

LENZ Therapeutics's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=220.003-17.334+0.75 * 0.442+0.5 * 4.121
=205.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics Change In Receivables Related Terms

LENZ Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics Change In Receivables Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
0.00 0.00 0.00 0.00 -0.33

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.01 -0.10
LENZ
12GF Score
LENZ Therapeutics Inc LENZ
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.11 Mil mean?
LENZ Therapeutics (LENZ) has a Change In Receivables of $-0.11 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for LENZ Therapeutics and its competitors.
Is LENZ Therapeutics' Change In Receivables too high?
LENZ Therapeutics' current Change In Receivables is $-0.11 Mil. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Change In Receivables compare to NGEN and ARMP?
LENZ Therapeutics' Change In Receivables of $-0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for LENZ Therapeutics and its competitors. LENZ Therapeutics's current Change In Receivables is $-0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Change In Receivables of $-0.11 Mil. The current Change In Receivables is $-0.11 Mil. LENZ Therapeutics' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Change In Receivables is $-0.11 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.74
Price